Government-Owned Inventions; Availability for Licensing, 46258-46259 [2021-17687]

Download as PDF 46258 Federal Register / Vol. 86, No. 157 / Wednesday, August 18, 2021 / Notices to plan, implement, and evaluate vaccination programs for influenza and COVID–19. Amount of Award: $47,000,000 in Federal Fiscal Year (FFY) 2021 funds, and an estimated total of $100,000,000 over the five-year period of performance, subject to availability of funds. Period of Performance: September 30, 2021 through September 29, 2026. Authority: Section 307 of the Public Health Service Act, as amended (42 U.S.C. 242l). Dated: August 12, 2021. Joseph I. Hungate III, Deputy Director, Office of Financial Resources, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2021–17678 Filed 8–17–21; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Administration for Children and Families Notice of Meeting Office on Trafficking in Persons, Administration for Children and Families, Department of Health and Human Services. ACTION: Announcement of meeting and call for public comments on states’ efforts to improve the nation’s response to the sex trafficking of children and youth. AGENCY: Notice is hereby given, pursuant to the provisions of the Federal Advisory Committee Act (FACA) and the Preventing Sex Trafficking and Strengthening Families Act, that a meeting of the National Advisory Committee on the Sex Trafficking of Children and Youth in the United States (the Committee) will be held on September 8 and 9, 2021. The purpose of the meeting is for the Committee to begin reviewing responses to the Committee’s State SelfAssessment Survey and develop a framework for the Committee’s final report. The members of the Committee request comments from the public to inform their ongoing work and final report. Please submit your comments to NAC@nhttac.org with the subject ‘‘NAC Comments’’ as soon as possible and before September 6, 2021. DATES: The meeting will be held on September 8 and 9, 2021. ADDRESSES: The meeting will be held virtually. Please register for this event online: https://www.acf.hhs.gov/otip/ jbell on DSKJLSW7X2PROD with NOTICES SUMMARY: VerDate Sep<11>2014 17:34 Aug 17, 2021 Jkt 253001 partnerships/national-advisorycommittee. FOR FURTHER INFORMATION, CONTACT: Katherine Chon (Designated Federal Officer) at EndTrafficking@acf.hhs.gov or (202) 205–5778, or 330 C Street SW, Washington, DC 20201. Additional information is available at https:// www.acf.hhs.gov/otip/partnerships/thenational-advisory-committee. SUPPLEMENTARY INFORMATION: The formation and operation on behalf of the Committee are governed by the provisions of Public Law 92–463, as amended (5 U.S.C. App. 2), which sets forth standards for the formation and use of federal advisory committees. Purpose of the Committee: The purpose of the Committee is to advise the Secretary and the Attorney General on practical and general policies concerning improvements to the nation’s response to the sex trafficking of children and youth in the United States. HHS established the Committee pursuant to Section 121 of the Preventing Sex Trafficking and Strengthening Families Act of 2014 (Pub. L. 113–183). Tentative Agenda: The agenda can be found at https://www.acf.hhs.gov/otip/ partnerships/the-national-advisorycommittee. To submit written statements, email NAC@nhttac.org, by September 6, 2021. Please include your name, organization, and phone number. More details on these options are below. Public Accessibility to the Meeting: Pursuant to 5 U.S.C. 552b and 41 CFR 102–3.140 through 102–3.165, and subject to the availability of space, this meeting is open to the public virtually. Written Statements: Pursuant to 41 CFR 102–3.105(j) and 102–3.140 and section 10(a)(3) of the Federal Advisory Committee Act, the public may submit written statements in response to the stated agenda of the meeting, or to the Committee’s mission, in general. Organizations with recommendations on strategies to engage states and stakeholders are encouraged to submit their comments or resources (hyperlinks preferred). Written comments or statements received after September 6, 2021, may not be provided to the Committee until its next meeting. Verbal Statements: Pursuant to 41 CFR 102–3.140d, the Committee is not obligated to allow a member of the public to speak or otherwise address the Committee during the meeting. Members of the public are invited to provide verbal statements during the Committee meeting only at the time and manner described in the agenda. The request to speak should include a brief statement of the subject matter to be PO 00000 Frm 00085 Fmt 4703 Sfmt 4703 addressed and should be relevant to the stated agenda of the meeting or the Committee’s mission in general. Minutes: The minutes of this meeting will be available for public review and copying within 90 days at: https:// www.acf.hhs.gov/otip/partnerships/thenational-advisory-committee. Linda Hitt, Director, Executive Secretariat. [FR Doc. 2021–17714 Filed 8–17–21; 8:45 am] BILLING CODE 4184–40–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Elizabeth Pitts, Ph.D., 240–669–5299; elizabeth.pitts@nih.gov. Licensing information may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496– 2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention. SUPPLEMENTARY INFORMATION: Technology description follows. SUMMARY: Tumor Associated Calcium Signal Transducer 2 (TACSTD2)Overexpressing Huh7.5 Cells That Are More Permissive to HCV Cell Entry and Replication Compared to the Model Huh7.5 Cell Line Description of Technology Worldwide, 130–150 million individuals are chronically infected with hepatitis C virus (HCV), a major cause of liver-associated morbidity and mortality worldwide. Despite recent advances in antiviral drugs that can cure some individuals, a rapid decline of the E:\FR\FM\18AUN1.SGM 18AUN1 Federal Register / Vol. 86, No. 157 / Wednesday, August 18, 2021 / Notices global disease burden is hampered by remarkably high treatment costs and a high number of undiagnosed infections. Moreover, a significant number of patients develop resistance and additional treatment modalities may be needed to dramatically reduce the worldwide incidence of HCV infection. The subject cell line may be a useful tool for studying the mechanism of HCV cellular entry and replication and could be incorporated into an in vitro assay to measure the effectiveness of novel HCV targeted therapies or as a system for improved propagation of HCV in culture. By overexpressing TACSTD2 in Huh7.5 cells, scientists at the National Institute of Allergy and Infectious Diseases (NIAID) discovered that they could restore the cellular localization of two host cell HCV-entry factors that become dysregulated in hepatocellular carcinoma (HCC) cells. Overexpression of TACSTD2 makes Huh7.5 cells more broadly permissive to infection and replication by multiple HCV genotypes in comparison to the canonical Huh7.5 cell model. HCV does not replicate in malignant HCC cells, possibly caused in part by downregulation of TACSTD2 expression. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404. Potential Commercial Applications • Cell line to study hepatitis C virus infection and replication or propagate HCV in culture. • Cell line to study cancer. jbell on DSKJLSW7X2PROD with NOTICES Development Stage • Material. Inventors: Patrizia Farci and Vandana Sekhar (NIAID). Publication: Sekhar V, Pollicino T, Diaz G, Engle RE, Alayli F, Melis M, Kabat J, Tice A, Pomerenke A, AltanBonnet N, Zamboni F, Lusso P, Emerson SU, and Farci P. (2018) Infection with hepatitis C virus depends on TACSTD2, a regulator of claudin-1 and occludin highly downregulated in hepatocellular carcinoma. PLoS Pathog 14: e1006916. doi: 10.1371/journal.ppat.1006916. Licensing Contact: To license this technology, please contact Elizabeth Pitts, Ph.D., 240–669–5299; elizabeth.pitts@nih.gov, and reference E–040–2020. Dated: August 12, 2021. Surekha Vathyam, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2021–17687 Filed 8–17–21; 8:45 am] BILLING CODE 4140–01–P VerDate Sep<11>2014 17:34 Aug 17, 2021 Jkt 253001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Cancer Advisory Board. The meeting will be held as a virtual meeting and is open to the public as indicated below. Individuals who plan to view the virtual meeting and need special assistance or other reasonable accommodations to view the meeting should notify the Contact Person listed below in advance of the meeting. The meeting will be videocast and can be accessed from the NIH Videocasting and Podcasting website (https:// videocast.nih.gov/). A portion of the National Cancer Advisory Board meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Advisory Board. Date: August 31, 2021. Open: 1:00 p.m. to 3:10 p.m. Agenda: NCAB Subcommittee Meetings— Subcommittee on Planning and Budget and Ad Hoc Subcommittee on Global Cancer Research. Place: National Cancer Institute—Shady Grove, 9609 Medical Center Drive, Rockville, MD 20850 (Virtual Meeting). Name of Committee: National Cancer Advisory Board. Date: September 1, 2021. Open: 1:00 p.m. to 4:15 p.m. Agenda: Director’s and Program reports and presentations; business of the Board. Closed: 4:25 p.m. to 5:30 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute—Shady Grove, 9609 Medical Center Drive, Rockville, MD 20850 (Virtual Meeting). Contact Person: Paulette S. Gray, Ph.D., Director, Division of Extramural Activities, National Cancer Institute—Shady Grove, National Institutes of Health, 9609 Medical Center Drive, 7th Floor, Room 7W444, Bethesda, MD 20892, 240–276–6340, grayp@ mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on PO 00000 Frm 00086 Fmt 4703 Sfmt 4703 46259 this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Information is also available on the Institute’s/Center’s home page: NCAB: https://deainfo.nci.nih.gov/advisory/ncab/ ncabmeetings.htm, where an agenda and any additional information for the meetings will be posted when available. This notice is being published less than 15 days prior to the meeting due to scheduling difficulties. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: August 13, 2021. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2021–17742 Filed 8–17–21; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Nursing Research; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Council for Nursing Research. The meeting will be open to the public as indicated below via videocast. The URL link to this meeting is https:// videocast.nih.gov/watch=42425. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory Council for Nursing Research. Date: September 14, 2021. Open: 11:00 a.m. to 3:30 p.m. E:\FR\FM\18AUN1.SGM 18AUN1

Agencies

[Federal Register Volume 86, Number 157 (Wednesday, August 18, 2021)]
[Notices]
[Pages 46258-46259]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-17687]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Elizabeth Pitts, Ph.D., 240-669-5299; 
[email protected]. Licensing information may be obtained by 
communicating with the indicated licensing contact at the Technology 
Transfer and Intellectual Property Office, National Institute of 
Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 
20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement 
will be required to receive copies of unpublished information related 
to the invention.

SUPPLEMENTARY INFORMATION: Technology description follows.

Tumor Associated Calcium Signal Transducer 2 (TACSTD2)-Overexpressing 
Huh7.5 Cells That Are More Permissive to HCV Cell Entry and Replication 
Compared to the Model Huh7.5 Cell Line

Description of Technology

    Worldwide, 130-150 million individuals are chronically infected 
with hepatitis C virus (HCV), a major cause of liver-associated 
morbidity and mortality worldwide. Despite recent advances in antiviral 
drugs that can cure some individuals, a rapid decline of the

[[Page 46259]]

global disease burden is hampered by remarkably high treatment costs 
and a high number of undiagnosed infections. Moreover, a significant 
number of patients develop resistance and additional treatment 
modalities may be needed to dramatically reduce the worldwide incidence 
of HCV infection. The subject cell line may be a useful tool for 
studying the mechanism of HCV cellular entry and replication and could 
be incorporated into an in vitro assay to measure the effectiveness of 
novel HCV targeted therapies or as a system for improved propagation of 
HCV in culture.
    By overexpressing TACSTD2 in Huh7.5 cells, scientists at the 
National Institute of Allergy and Infectious Diseases (NIAID) 
discovered that they could restore the cellular localization of two 
host cell HCV-entry factors that become dysregulated in hepatocellular 
carcinoma (HCC) cells. Overexpression of TACSTD2 makes Huh7.5 cells 
more broadly permissive to infection and replication by multiple HCV 
genotypes in comparison to the canonical Huh7.5 cell model. HCV does 
not replicate in malignant HCC cells, possibly caused in part by 
downregulation of TACSTD2 expression.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404.

Potential Commercial Applications

     Cell line to study hepatitis C virus infection and 
replication or propagate HCV in culture.
     Cell line to study cancer.

Development Stage

     Material.
    Inventors: Patrizia Farci and Vandana Sekhar (NIAID).
    Publication: Sekhar V, Pollicino T, Diaz G, Engle RE, Alayli F, 
Melis M, Kabat J, Tice A, Pomerenke A, Altan-Bonnet N, Zamboni F, Lusso 
P, Emerson SU, and Farci P. (2018) Infection with hepatitis C virus 
depends on TACSTD2, a regulator of claudin-1 and occludin highly 
downregulated in hepatocellular carcinoma. PLoS Pathog 14: e1006916. 
doi: 10.1371/journal.ppat.1006916.
    Licensing Contact: To license this technology, please contact 
Elizabeth Pitts, Ph.D., 240-669-5299; [email protected], and 
reference E-040-2020.

    Dated: August 12, 2021.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2021-17687 Filed 8-17-21; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.